



## MEDIA RELEASE

**For Immediate Release**

### **Nationally Recognized Ophthalmologist Dr. Elizabeth Yeu Joins Avellino's Board of Directors**

*Dr. Yeu brings her deep knowledge in ophthalmology and the latest industry innovations to further accelerate Avellino's ophthalmic research and product pipeline*

**MENLO PARK, Calif. – (Jan. 5, 2022)** – Avellino Lab USA, Inc. (Avellino) today announced the appointment of Dr. Elizabeth Yeu to the company's Board of Directors. Dr. Yeu will also remain a member of Avellino's Scientific and Medical Advisory Board.

A board-certified physician, Dr. Yeu is a nationally recognized leader and influential physician and educator in the eye care industry. She is a leading expert and lecturer, frequently speaking on the topics of refractive corneal and cataract surgery, ocular surface disease and anterior segment reconstruction and is the author of hundreds of medical articles.

As an Executive Committee member of Virginia Eye Consultants, Dr. Yeu is actively involved in clinical research of new technologies and therapies to enhance patient vision and overall ocular health, and is committed to exceptional patient outcomes by incorporating novel therapeutics and advanced surgical techniques.

Her depth of experience will help Avellino as the company continues to provide genetic-based diagnostics for the ophthalmic industry and expands its innovative product pipeline to new disease areas such as glaucoma.

"We are thrilled to have Dr. Elizabeth Yeu join our board of directors with her exceptional experience in eye care and depth of knowledge," says Avellino Founder and Chairman Gene Lee. "Avellino was created with a desire to help prevent unnecessary risk from refractive surgery, and Dr. Yeu's talents and dedication to positive patient outcomes will help accelerate our growing suite of genetic tests for the eye."

"Dr. Yeu is a leading authority in ophthalmology and her experience and commitment to her patients makes her an ideal addition to our Board as we continue to develop innovative solutions for both the ophthalmic industry and beyond," says Avellino CEO Jon Robson. "On behalf of the entire board of directors and executive team, we welcome Dr. Yeu and we greatly look forward to partnering with her as we continue our mission to improve human health."

In addition to her clinical practice with Virginia Eye Consultants, Dr. Yeu is Chief Medical Advisor for Tarsus Pharmaceuticals, serves as a Director for the Board for both STAAR Surgical and Ocular Science, and is the Chief Strategic Advisor for ACE Vision Group.

Dr. Yeu earned her Bachelor of Science and her M.D. from an accelerated academic program through the University of Florida, Gainesville and the UF College of Medicine. She completed her ophthalmology residency at Rush University Medical Center in Chicago, where she served as Chief Resident. Dr. Yeu then went to the Cullen Eye Institute, Baylor College of Medicine to complete a Fellowship in Cornea, Anterior Segment and Refractive Surgery where she served as an Assistant Professor until 2013. Dr. Yeu joined Virginia Eye Consultants in 2013 and became a partner in 2014, and she continues her commitment to residency training in ophthalmology as an Assistant Professor at the Eastern Virginia Medical School. She is the Medical Director at the Virginia Surgery Center and also sits on the Board of Directors with the Virginia Eye Foundation.

### **About Avellino**

Avellino Lab USA, Inc. is a global leader in genetic molecular diagnostics at the forefront of precision medicine for eye care. With a long-term mission to develop personalized approaches to improve health and disease management through genomics, the company is developing a transformative genetic diagnostics product pipeline, as well as genetic therapeutics leveraging CRISPR gene editing, to better manage, and potentially cure, inherited diseases. The company also developed the Avellino SARS-CoV-2 RT-PCR diagnostic test to aid in COVID-19 pandemic testing efforts in the U.S. The third private company in the U.S. to receive EUA for its COVID-19 test, Avellino has performed more than 2.5 million COVID-19 related tests. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, China and the UK.

To learn more about Avellino, visit [www.avellino.com](http://www.avellino.com).

# # #

### **Media Contact**

Angela Lapré

[Angela.Lapre@Avellino.com](mailto:Angela.Lapre@Avellino.com)

650-788-0374